...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Obstetrics and Gynecology >Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors
【24h】

Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors

机译：人体上皮性卵巢肿瘤中的大麻素1型受体免疫反应性和疾病严重性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective In light of recent findings indicating that endocannabinoid system has antitumor actions, our study aimed to localize it in the human epithelial ovarian tumors, highlighting the differences among benign, borderline, and invasive forms and correlating cannabinoid receptor type 1 (CB1R) expression with disease severity. Study Design We determined CB1R immunohistochemical expression in 66 epithelial ovarian tumors treated in the Department of Woman, Child, and General and Specialized Surgery, Second University of Naples, at S. Maria del Popolo degli Incurabili Hospital (Naples): 36 borderline ovarian tumors, the main target of interest being intermediate forms, 15 benign and 15 invasive ovarian tumors. Results The benign ovarian tumors showed a weak expression of CB1R in the 33% of the cases and moderate expression in the 67% of the cases. Borderline ovarian tumors had a similar trend. They showed weak CB1R expression in 28% of the cases, moderate expression in 53% of the cases, and strong expression in 19% of the cases. In contrast, invasive tumors showed a weak expression of CB1R in 7% of the cases, moderate expression in 20% of the cases, and strong expression in 73% of the cases. Conclusion The recorded data show that the expression of CB1R increased from benign and borderline to malignant tumors. In the near future, endocannabinoid receptors might be used in clinical practice, alone or in combination with other markers, to identify or better characterize ovarian tumors, without considering the great opportunity that they might represent as therapeutic targets.
机译：目的鉴于最近的发现表明内源性大麻素系统具有抗肿瘤作用，我们的研究旨在将其定位于人类上皮性卵巢肿瘤中，强调良性，边界性和侵入性形式之间的差异，并使大麻素受体1型（CB1R）表达与疾病相关严重性。研究设计我们确定了那不勒斯第二大学S. Maria del Popolo degli Incurabili医院（那不勒斯）妇女，儿童及普通外科和专科外科治疗的66例上皮性卵巢肿瘤中的CB1R免疫组织化学表达：36个交界性卵巢肿瘤，感兴趣的主要靶标是中间形式，15种良性和15种侵袭性卵巢肿瘤。结果良性卵巢肿瘤在33％的病例中表现为CB1R弱表达，在67％的病例中表现为中度表达。交界性卵巢肿瘤也有类似的趋势。他们在28％的病例中表现出弱的CB1R表达，在53％的病例中表现出中等表达，在19％的病例中表现出强烈的表达。相反，浸润性肿瘤在7％的病例中表现出CB1R的弱表达，在20％的病例中表现为中度表达，而在73％的病例中表现出强表达。结论所记录的数据表明，CB1R的表达从良性和临界性上升为恶性肿瘤。在不久的将来，内源性大麻素受体可能会单独或与其他标志物结合用于临床实践，以鉴定或更好地表征卵巢肿瘤，而无需考虑它们可能代表治疗靶点的巨大机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号